AngioDynamics (ANGO) 10-Q 8 Jan 25 2025 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Nov. 30, 2024	Jan. 07, 2025
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Nov. 30, 2024
Document Transition Report	false
Entity File Number	0-50761
Entity Registrant Name	AngioDynamics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3146460
Entity Address, Address Line One	14 Plaza Drive
Entity Address, City or Town	Latham
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12110
City Area Code	518
Local Phone Number	795-1400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		40,465,709
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $.01
Trading Symbol	ANGO
Security Exchange Name	NASDAQ
Preferred Stock Purchase Rights
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Income Statement [Abstract]
Net sales	$ 72,845	$ 79,073	$ 140,336	$ 157,752
Cost of sales (exclusive of intangible amortization)	32,939	38,811	63,706	77,430
Gross profit	39,906	40,262	76,630	80,322
Operating expenses:
Research and development	6,434	8,658	12,719	16,599
Sales and marketing	25,589	25,464	51,194	52,832
General and administrative	10,391	9,289	21,366	20,145
Amortization of intangibles	2,562	3,562	5,132	7,187
Change in fair value of contingent consideration	156	221	232	91
Acquisition, restructuring and other items, net	5,868	6,188	10,179	9,400
Total operating expenses	51,000	53,382	100,822	106,254
Gain on sale of assets	0	0	0	47,842
Operating income (loss)	(11,094)	(13,120)	(24,192)	21,910
Other expense:
Interest income, net	234	534	840	653
Other income (expense), net	12	(32)	(161)	(320)
Total other income, net	246	502	679	333
Income (loss) before income tax benefit	(10,848)	(12,618)	(23,513)	22,243
Income tax expense (benefit)	(110)	16,430	23	5,407
Net income (loss)	$ (10,738)	$ (29,048)	$ (23,536)	$ 16,836
Earnings (loss) per share
Loss per share, basic (USD per share)	$ (0.26)	$ (0.72)	$ (0.58)	$ 0.42
Loss per share, diluted (USD per share)	$ (0.26)	$ (0.72)	$ (0.58)	$ 0.42
Weighted average shares outstanding
Basic weighted average shares outstanding (in shares)	40,922	40,219	40,787	40,030
Diluted weighted average shares outstanding (in shares)	40,922	40,219	40,787	40,103

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (10,738)	$ (29,048)	$ (23,536)	$ 16,836
Other comprehensive income (loss), before tax:
Foreign currency translation gain (loss)	(481)	945	617	15
Other comprehensive income (loss), before tax	(481)	945	617	15
Income tax expense related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(481)	945	617	15
Total comprehensive income (loss), net of tax	$ (11,219)	$ (28,103)	$ (22,919)	$ 16,851

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Current assets
Cash and cash equivalents	$ 54,089	$ 76,056
Accounts receivable, net of allowances of $2,440 and $2,141 respectively	43,158	43,610
Inventories	65,918	60,616
Prepaid expenses and other	12,195	12,971
Total current assets	175,360	193,253
Property, plant and equipment, net	32,977	35,666
Intangible assets, net	73,110	77,383
Other assets	10,103	11,369
Total assets	291,550	317,671
Current liabilities
Accounts payable	34,746	37,751
Accrued liabilities	39,919	41,098
Current portion of contingent consideration	4,960	4,728
Other current liabilities	8,970	7,578
Total current liabilities	88,595	91,155
Deferred income taxes	4,334	4,852
Other long-term liabilities	11,853	16,078
Total liabilities	104,782	112,085
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 41,449,556 and 40,801,597 shares issued and 40,835,709 and 40,431,597 shares outstanding at November 30, 2024 and May 31, 2024, respectively	384	385
Additional paid-in capital	616,253	610,484
Accumulated deficit	(418,740)	(395,204)
Treasury stock, 613,847 and 370,000 shares at November 30, 2024 and May 31, 2024, respectively	(7,381)	(5,714)
Accumulated other comprehensive loss	(3,748)	(4,365)
Total Stockholders’ Equity	186,768	205,586
Total Liabilities and Stockholders' Equity	$ 291,550	$ 317,671

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 2,440	$ 2,141
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	41,449,556	40,801,597
Common stock, shares outstanding (in shares)	40,835,709	40,431,597
Treasury stock, shares (in shares)	613,847	370,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ (23,536)	$ 16,836
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	13,648	13,373
Non-cash lease expense	993	957
Stock based compensation	5,733	6,021
Gain on disposal of assets	0	(47,842)
Transaction costs for disposition	0	(2,427)
Change in fair value of contingent consideration	232	91
Deferred income taxes	(588)	4,951
Change in accounts receivable allowances	388	549
Fixed and intangible asset impairments and disposals	59	239
Write-off of other assets	0	869
Other	119	(138)
Changes in operating assets and liabilities:
Accounts receivable	50	677
Inventories	(5,303)	(8,844)
Prepaid expenses and other	(72)	(4,979)
Accounts payable, accrued and other liabilities	(7,503)	(966)
Net cash used in operating activities	(15,780)	(20,633)
Cash flows from investing activities:
Additions to property, plant and equipment	(1,889)	(1,345)
Additions to placement and evaluation units	(2,477)	(2,006)
Proceeds from sale of assets	0	100,000
Net cash (used in) provided by investing activities	(4,366)	96,649
Cash flows from financing activities:
Repayment of long-term debt	0	(50,000)
Payment of acquisition related contingent consideration	0	(10,000)
Repurchase of common stock	(1,670)	0
Proceeds from exercise of stock options and employee stock purchase plan	38	58
Net cash used in financing activities	(1,632)	(59,942)
Effect of exchange rate changes on cash and cash equivalents	(189)	202
Increase (decrease) in cash and cash equivalents	(21,967)	16,276
Cash and cash equivalents at beginning of period	76,056	44,620
Cash and cash equivalents at end of period	54,089	60,896
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period	$ 411	$ (138)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Restricted stock units	Performance share units	Common Stock	Common Stock Restricted stock units	Common Stock Performance share units	Additional paid in capital	Additional paid in capital Restricted stock units	Additional paid in capital Performance share units	Accumulated deficit	Accumulated other comprehensive loss	Treasury Stock
Beginning Balance (in shares) at May. 31, 2023				39,981,422,000
Beginning Balance at May. 31, 2023	$ 378,296			$ 382			$ 599,206			$ (210,855)	$ (4,723)	$ (5,714)
Beginning Balance, Treasury Stock (in shares) at May. 31, 2023												(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	45,884									45,884
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)					386,031,000	87,377,000
Issuance/Cancellation of performance share units and restricted stock units		$ (280)	$ (210)					$ (280)	$ (210)
Purchase of common stock under ESPP (in shares)				131,811,000
Purchases of common stock under ESPP	900			$ 1			899
Stock-based compensation	4,144						4,144
Other comprehensive loss, net of tax	(930)										(930)
Ending Balance (in shares) at Aug. 31, 2023				40,586,641,000
Ending Balance at Aug. 31, 2023	427,804			$ 383			603,759			(164,971)	(5,653)	$ (5,714)
Ending Balance, Treasury Stock (in shares) at Aug. 31, 2023												(370,000,000)
Beginning Balance (in shares) at May. 31, 2023				39,981,422,000
Beginning Balance at May. 31, 2023	378,296			$ 382			599,206			(210,855)	(4,723)	$ (5,714)
Beginning Balance, Treasury Stock (in shares) at May. 31, 2023												(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	16,836
Ending Balance (in shares) at Nov. 30, 2023				40,594,406,000
Ending Balance at Nov. 30, 2023	401,226			$ 383			605,284			(194,019)	(4,708)	$ (5,714)
Ending Balance, Treasury Stock (in shares) at Nov. 30, 2023												(370,000,000)
Beginning Balance (in shares) at Aug. 31, 2023				40,586,641,000
Beginning Balance at Aug. 31, 2023	427,804			$ 383			603,759			(164,971)	(5,653)	$ (5,714)
Beginning Balance, Treasury Stock (in shares) at Aug. 31, 2023												(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(29,048)									(29,048)
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)					7,765,000
Issuance/Cancellation of performance share units and restricted stock units		(16)	(336)					(16)	(336)
Stock-based compensation	1,877						1,877
Other comprehensive loss, net of tax	945										945
Ending Balance (in shares) at Nov. 30, 2023				40,594,406,000
Ending Balance at Nov. 30, 2023	401,226			$ 383			605,284			(194,019)	(4,708)	$ (5,714)
Ending Balance, Treasury Stock (in shares) at Nov. 30, 2023												(370,000,000)
Beginning Balance (in shares) at May. 31, 2024				40,801,597
Beginning Balance at May. 31, 2024	$ 205,586			$ 385			610,484			(395,204)	(4,365)	$ (5,714)
Beginning Balance, Treasury Stock (in shares) at May. 31, 2024	(370,000)											(370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (12,798)									(12,798)
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)					432,144	60,731
Issuance/Cancellation of performance share units and restricted stock units		(321)	$ (347)					(321)	$ (347)
Purchase of common stock under ESPP (in shares)				151,918
Purchases of common stock under ESPP	711			$ 2			709
Stock-based compensation	3,205						3,205
Common stock repurchased (in shares)												(72,141)
Common stock repurchased	(552)			$ (1)								$ (551)
Other comprehensive loss, net of tax	1,098										1,098
Ending Balance (in shares) at Aug. 31, 2024				41,446,390
Ending Balance at Aug. 31, 2024	196,582			$ 386			613,730			(408,002)	(3,267)	$ (6,265)
Ending Balance, Treasury Stock (in shares) at Aug. 31, 2024												(442,141)
Beginning Balance (in shares) at May. 31, 2024				40,801,597
Beginning Balance at May. 31, 2024	$ 205,586			$ 385			610,484			(395,204)	(4,365)	$ (5,714)
Beginning Balance, Treasury Stock (in shares) at May. 31, 2024	(370,000)											(370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (23,536)
Ending Balance (in shares) at Nov. 30, 2024				41,449,556
Ending Balance at Nov. 30, 2024	$ 186,768			$ 384			616,253			(418,740)	(3,748)	$ (7,381)
Ending Balance, Treasury Stock (in shares) at Nov. 30, 2024	(613,847)											(613,847)
Beginning Balance (in shares) at Aug. 31, 2024				41,446,390
Beginning Balance at Aug. 31, 2024	$ 196,582			$ 386			613,730			(408,002)	(3,267)	$ (6,265)
Beginning Balance, Treasury Stock (in shares) at Aug. 31, 2024												(442,141)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(10,738)									(10,738)
Issuance/Cancellation of performance share units and restricted stock units, net (in shares)					3,166
Issuance/Cancellation of performance share units and restricted stock units		$ (5)						$ (5)
Stock-based compensation	2,528						2,528
Common stock repurchased (in shares)												(171,706)
Common stock repurchased	(1,118)			$ (2)								$ (1,116)
Other comprehensive loss, net of tax	(481)										(481)
Ending Balance (in shares) at Nov. 30, 2024				41,449,556
Ending Balance at Nov. 30, 2024	$ 186,768			$ 384			$ 616,253			$ (418,740)	$ (3,748)	$ (7,381)
Ending Balance, Treasury Stock (in shares) at Nov. 30, 2024	(613,847)											(613,847)

Consolidated Financial Statemen

Consolidated Financial Statements	6 Months Ended
	Nov. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended November 30, 2024 and 2023, the Consolidated Balance Sheet as of November 30, 2024, the Consolidated Statements of Cash Flows for the six months ended November 30, 2024 and 2023, and the Consolidated Statements of Stockholders’ Equity for the six months ended November 30, 2024 and 2023 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2024 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2024 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three and six months ended November 30, 2024 and 2023 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.

Divestitures

Divestitures	6 Months Ended
	Nov. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	DIVESTITURES PICCs and Midlines Pursuant to an asset purchase agreement dated February 15, 2024 (the "Asset Purchase Agreement"), the Company completed the sale of the PICC and Midline businesses (the "Divestiture") to Spectrum Vascular ("Spectrum"). Total consideration received by the Company for the Divestiture in the third quarter of fiscal year 2024 was $34.5 million in cash and resulted in a pre-tax book gain of $6.7 million. Included in the agreement is a $5.5 million earn-out related to the sales of divested products over a two-year period and a milestone payment of $5.0 million paid upon final transfer of the manufacturing to a third-party that Spectrum will pay to the Company upon achievement. The Company and Spectrum entered into various agreements to facilitate the transition of the divested businesses to Spectrum, including a Transition Services Agreement and Contract Manufacturing Agreement. The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company's operations or financial results and as a result, this transaction is not classified as discontinued operations. The following table summarizes the major classes of assets sold on the date of the sale: (in thousands) As of February 15, 2024 Current assets: Inventories $ 4,203 Total current assets $ 4,203 Non-current assets: Property, plant and equipment, net $ 158 Intangible assets, net 20,781 Other assets 40 Total non-current assets $ 20,979 Dialysis and BioSentry Pursuant to an asset purchase agreement dated June 8, 2023 (the "Asset Purchase Agreement"), the Company completed the sale of the dialysis and BioSentry tract sealant system biopsy businesses (the "Divestiture") to Merit Medical Systems, Inc. ("Merit"). Total consideration received by the Company for the Divestiture in the first quarter of fiscal year 2024 was $100.0 million in cash and resulted in a pre-tax book gain of $47.8 million. The Company and Merit entered into various agreements to facilitate the transition of the divested businesses to Merit, including a Transition Services Agreement and Contract Manufacturing Agreement. The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company's operations or financial results and as a result, this transaction will not be classified as discontinued operations. The following table summarizes the major classes of assets sold on the date of the sale: (in thousands) As of June 8, 2023 Current assets: Inventories $ 4,068 Prepaid expenses and other 2,000 Total current assets $ 6,068 Non-current assets: Property, plant and equipment, net $ 54 Intangible assets, net 17,629 Goodwill 25,980 Total non-current assets $ 43,663

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Nov. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Under ASC 606, Revenue from Contracts with Customers , revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has one primary revenue stream which is the sales of its products. Disaggregation of Revenue The following table summarizes net sales by Med Tech, Med Device and by geography: Three Months Ended November 30, 2024 Three Months Ended November 30, 2023 (in thousands) United States International Total United States International Total Net sales Med Tech $ 27,134 $ 4,420 $ 31,554 $ 20,947 $ 4,416 $ 25,363 Med Device 35,544 5,747 41,291 43,055 10,655 53,710 Total $ 62,678 $ 10,167 $ 72,845 $ 64,002 $ 15,071 $ 79,073 Six Months Ended November 30, 2024 Six Months Ended November 30, 2023 (in thousands) United States International Total United States International Total Net sales Med Tech $ 52,023 $ 7,500 $ 59,523 $ 43,189 $ 8,035 $ 51,224 Med Device 70,136 10,677 80,813 85,212 21,316 106,528 Total $ 122,159 $ 18,177 $ 140,336 $ 128,401 $ 29,351 $ 157,752 Net Product Revenue The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. Contracts and Performance Obligations The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposable revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations. Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the six months ended November 30, 2024 and 2023, such product returns were not material. Contract Balances with Customers A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets. The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Nov 30, 2024 May 31, 2024 Receivables $ 43,158 $ 43,610 Contract assets $ — $ — Contract liabilities $ 56 $ 391 During the six months ended November 30, 2024, the Company had additions to contract liabilities of $0.2 million. This was offset by $0.2 million in revenue that was recognized during the six months ended November 30, 2024. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.

Inventories

Inventories	6 Months Ended
	Nov. 30, 2024
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Nov 30, 2024 May 31, 2024 Raw materials $ 28,445 $ 30,736 Work in process 6,596 6,772 Finished goods 30,877 23,108 Inventories $ 65,918 $ 60,616

Intangible Assets

Intangible Assets	6 Months Ended
	Nov. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	INTANGIBLE ASSETS Definite Lived Intangible Assets Intangible assets are amortized over their estimated useful lives on a straight-line basis. Useful lives range from two Intangible assets consisted of the following: Nov 30, 2024 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 177,540 $ (107,792) $ 69,748 Customer relationships 8,996 (5,823) 3,173 Trademarks 2,100 (2,052) 48 Licenses 3,837 (3,696) 141 $ 192,473 $ (119,363) $ 73,110 May 31, 2024 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 176,227 $ (102,468) $ 73,759 Customer relationships 9,028 (5,628) 3,400 Trademarks 2,100 (2,024) 76 Licenses 3,837 (3,689) 148 $ 191,192 $ (113,809) $ 77,383 Amortization expense for the three months ended November 30, 2024 and 2023 was $2.6 million and $3.6 million, respectively. Amortization expense for the six months ended November 30, 2024 and 2023 was $5.1 million and $7.2 million, respectively. Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows: (in thousands) Remainder of 2025 $ 5,178 2026 10,175 2027 10,085 2028 10,036 2029 9,938 2030 and thereafter 27,698 $ 73,110

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Nov. 30, 2024
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES Accrued liabilities consisted of the following: (in thousands) Nov 30, 2024 May 31, 2024 Payroll and related expenses $ 13,139 $ 15,920 Outside services 8,982 8,962 Research and development 1,552 1,255 Royalties 2,088 2,575 Sales and franchise taxes 861 520 Deferred warranties 398 460 TSA Payable 6,459 6,259 Rebates 455 412 Accrued Freight 450 575 Accrued severance 1,524 1,486 Other 4,011 2,674 $ 39,919 $ 41,098

Income Taxes

Income Taxes	6 Months Ended
	Nov. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 1.7% as of the second quarter of fiscal year 2025, as compared to 23.7% for the same period in fiscal year 2024. In fiscal year 2025, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation). The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets as of November 30, 2024. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Nov. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”), and authorized an initial reserve of 2.4 million shares of common stock available for grants. The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 3, 2022 and November 14, 2023, the Company’s shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for grants by 1.95 million shares and 1.5 million shares, respectively. On November 12, 2024, the Company's shareholders approved an additional amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 3.2 million shares. As of November 30, 2024, there was a maximum of 4.1 million shares of common stock available for future grant under the 2020 Plan. Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan. The Company also has an employee stock purchase plan. As of November 30, 2024, there was a maximum of 2.7 million shares of common stock available for future grant under the employee stock purchase plan. For the three months ended November 30, 2024 and 2023, share-based compensation expense was $2.5 million and $1.9 million, respectively. For the six months ended November 30, 2024 and 2023, share-based compensation expense was $5.7 million and $6.0 million, respectively. During the six months ended November 30, 2024 and 2023, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Generally, restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award. In July 2023, the Board of Directors approved a change in terms of restricted stock units granted to non-employee directors to provide for immediate vesting upon grant of the award. During the six months ended November 30, 2024 and 2023, the Company granted performance share units under the 2020 Plan to certain employees. The awards may be earned by achieving performance levels over the requisite service period. The performance criteria are based on achieving certain performance targets and the total shareholder return (“TSR”) of the Company’s common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards is based on a Monte Carlo simulation model.

Equity

Equity	6 Months Ended
	Nov. 30, 2024
Equity [Abstract]
Equity	EQUITYOn July 16, 2024, the Board of Directors approved a share repurchase program (the "Repurchase Program") under which they authorized the Company the option to repurchase up to $15.0 million of its outstanding common stock. The timing and amount of any share repurchases under the authorization will be determined by management within certain parameters and based on market conditions and other considerations. During the second quarter of fiscal year 2025, the Company repurchased 171,706 shares of common stock in the open market at an aggregate cost of $1.1 million under the Repurchase Program. During the first quarter of fiscal year 2025, the Company repurchased 72,141 shares of common stock in the open market at an aggregate cost of $0.5 million under the Repurchase Program. As of November 30, 2024, $13.3 million remained available for repurchase under the Repurchase Program.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Nov. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive. The following table reconciles basic to diluted weighted-average shares outstanding: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Basic 40,922 40,219 40,787 40,030 Effect of dilutive securities — — — 73 Diluted 40,922 40,219 40,787 40,103 Securities excluded as their inclusion would be anti-dilutive 5,099 4,361 5,099 3,955

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Nov. 30, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION Segment information The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources. The Company manages its operations through two segments, Med Tech and Med Device. The CEO evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment. Total assets were $291.6 million as of November 30, 2024. The table below summarizes net sales and gross margin by Med Tech and Med Device: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Med Tech net sales $ 31,554 $ 25,363 $ 59,523 $ 51,224 Gross profit 20,113 15,816 37,810 32,543 Gross margin 63.7 % 62.4 % 63.5 % 63.5 % Med Device net sales $ 41,291 $ 53,710 80,813 $ 106,528 Gross profit 19,793 24,446 38,820 $ 47,779 Gross margin 47.9 % 45.5 % 48.0 % 44.9 % Total net sales $ 72,845 $ 79,073 $ 140,336 $ 157,752 Gross profit 39,906 40,262 76,630 80,322 Gross margin 54.8 % 50.9 % 54.6 % 50.9 % Geographic information The table below summarizes net sales by geographic area based on external customer location: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Net Sales United States $ 62,678 $ 64,002 $ 122,159 $ 128,401 International 10,167 15,071 18,177 29,351 Total $ 72,845 $ 79,073 $ 140,336 $ 157,752

Fair Value

Fair Value	6 Months Ended
	Nov. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities. The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: Fair Value at Nov 30, 2024 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 4,960 $ 4,960 Total Financial Liabilities $ — $ — $ 4,960 $ 4,960 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2024 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 4,728 $ 4,728 Total Financial Liabilities $ — $ — $ 4,728 $ 4,728 There were no transfers between Level 1, 2 and 3 for the three and six months ended November 30, 2024 and 2023. The table below presents the changes in fair value components of Level 3 instruments: Three Months Ended Nov 30, 2024 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, August 31, 2024 $ 4,804 Change in present value of contingent consideration (1) 156 Balance, November 30, 2024 $ 4,960 Six Months Ended November 30, 2024 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2024 $ 4,728 Change in present value of contingent consideration (1) 232 Balance, November 30, 2024 $ 4,960 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. Contingent Liability for Acquisition Earn Outs Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2024: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 4,960 Discounted cash flow Discount rate 10% Probability of payment 100% Projected fiscal year of payment 2025

Leases

Leases	6 Months Ended
	Nov. 30, 2024
Leases [Abstract]
Leases	LEASES The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Nov 30, 2024 May 31, 2024 Assets Operating lease ROU asset Other assets $ 4,803 $ 5,804 Liabilities Current operating lease liabilities Other current liabilities 1,878 1,975 Non-current operating lease liabilities Other long-term liabilities 3,030 3,939 Total lease liabilities $ 4,908 $ 5,914 The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate: Nov 30, 2024 Weighted average remaining term (in years) 3.08 Weighted average discount rate 4.7 % The maturities of the lease liabilities for each of the following fiscal years is: (in thousands) Nov 30, 2024 Remainder of 2025 $ 1,077 2026 1,971 2027 983 2028 729 2029 and thereafter 515 Total lease payments $ 5,275 Less: imputed interest 367 Total lease obligations $ 4,908 Less: Current portion of lease obligations 1,878 Long-term lease obligations $ 3,030 During the three months ended November 30, 2024 and 2023, the Company recognized $0.7 million and $0.6 million of operating lease expense, respectively, which includes immaterial short-term leases. During the six months ended November 30, 2024 and 2023, the Company recognized $1.3 million and $1.3 million of operating lease expense respective, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Cost of sales $ 230 $ 219 $ 461 $ 416 Research and development 88 39 197 97 Sales and marketing 40 40 80 80 General and administrative 298 329 599 661 $ 656 $ 627 $ 1,337 $ 1,254 The following table presents supplemental cash flow and other information related to leases: Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,120 $ 1,064 ROU assets obtained in exchange for lease liabilities Operating leases $ — $ 381

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Nov. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")). On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The Court entered Judgement on June 1, 2023 in favor of the Company. On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 and 9,603,993. The Company counterclaimed, alleging that certain of Bard’s catheter products infringe U.S. Patent Nos. 8,377,011, 10,729,881, 8,454,574. On March 31, 2024, the Company and Bard’s parent company Becton, Dickinson and Company (collectively, “BD”) entered into a settlement agreement (the “Settlement Agreement”) to resolve the ongoing litigations. Under the terms of the Settlement Agreement, BD granted a license to the Company under certain of BD’s port patents and AngioDynamics granted BD a license under certain of the Company’s catheter patents. The Company made a one-time lump sum payment to BD in the amount of $7.0 million, $3.0 million which was paid within 5 business days of execution of the Settlement Agreement, and the remainder is payable in installments during 12 month period ending March 31, 2025. The Company will also make six minimum annual payments to BD of $2.5 million starting in fiscal year 2025, and potential additional payments if six percent (6%) of annual net sales of the Company’s port products exceed the minimum payment. The parties will participate in the pending appeal before the Federal Circuit of the case that was filed March 10, 2015 and a contingent payment of $3.0 million will be due from the Company to BD if the Federal Circuit reverses or vacates the District Court’s findings of invalidity with respect to the patent claims at issue in the case. Appellate briefing is closed, but an argument date has not yet been set. Neither party admitted any liability and the agreement contains mutual covenants not to sue and releases. As of November 30, 2024, there was $7.0 million payable to BD recorded in other current liabilities and $8.8 million recorded in other long-term liabilities. Port Product Claims

Acquisition, Restructuring and

Acquisition, Restructuring and Other Items, Net	6 Months Ended
	Nov. 30, 2024
Restructuring and Related Activities [Abstract]
Acquisition, Restructuring and Other Items, Net	ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET Acquisition, Restructuring and Other Items Acquisition, restructuring and other items, net, consisted of: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Legal (1) $ 56 $ 5,322 $ 410 $ 7,139 Mergers and acquisitions 737 252 737 252 Plant closure (2) 5,102 — 8,691 — Transition service agreement (3) (454) (177) (960) (323) Manufacturing relocation (4) — 689 — 1,277 Other (5) 427 102 1,301 1,055 Total $ 5,868 $ 6,188 $ 10,179 $ 9,400 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Plant closure expenses, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024. (3) Transition services agreements that were entered into with Merit and Spectrum. (4) Expenses to relocate certain manufacturing lines out of Queensbury, NY. (5) Included in the $1.1 million in other for the six months ended November 30, 2023 is $0.9 million of deferred financing fees that were written-off in conjunction with the sale of the Dialysis and BioSentry businesses and concurrent extinguishment of the debt. Restructuring The Company evaluates its performance and looks for opportunities to improve the overall operations of the Company on an ongoing basis. As a result of this evaluation, certain restructuring initiatives are taken to enhance the Company’s overall operations. On January 5, 2024, the Company announced a restructuring of its manufacturing footprint and a shift to an outsourced model (the "Plan"). This Plan will transfer all product manufacturing processes to third-party manufacturers. In the second quarter of fiscal year 2025, the Company announced a modification to the Plan to maintain a presence in Queensbury, NY for the manufacturing of select products, customer service, logistics, shipping, quality and regulatory operations. The restructuring activities associated with the modified Plan are still expected to be completed in the third quarter of fiscal year 2026. The following table provides a summary of our estimated costs associated with the original and modified Plan: Type of cost (in thousands) Total original estimated amount expected to be incurred Total modified estimated amount expected to be incurred Facilities closeout fees (1) $ 14,500 to $ 15,250 $ 16,000 to $ 17,000 Termination benefits 9,000 to 10,000 6,200 to 7,200 Outside consultants 9,000 to 10,000 7,500 to 8,500 Validation expenses 4,500 to 5,500 3,400 to 4,400 Regulatory filings 750 to 1,250 150 to 650 Other 750 to 1,250 150 to 650 $ 38,500 to $ 43,250 $ 33,400 to $ 38,400 (1) Included in the original and modified estimate is approximately $13.6 million and $13.3 million of non-cash charges for accelerated depreciation and building impairment, respectively. The Company recorded restructuring charges related to the plan during the three and six months ended November 30, 2024 of $5.1 million and $8.7 million, respectively. Total restructuring charges recorded to date are $18.2 million. Termination benefits are only earned if an employee stays until their termination date; therefore, the expenses related to termination benefits are being recorded ratably over the service period. The table below presents the restructuring reserve for the three and six months ended November 30, 2024 : Three Months Ended Nov 30, 2024 Termination Benefits Outside Consultants Validation Expenses Facilities Closeout Fees Regulatory Filings Other Total (in thousands) Balance at August 31, 2024 $ 855 $ 994 $ 682 $ — $ — $ 74 $ 2,605 Charges 276 2,681 482 1,293 9 361 5,102 Non-cash adjustments — — — (1,293) — — (1,293) Cash payments — (1,671) (716) — (9) (295) (2,691) Balance at November 30, 2024 $ 1,131 $ 2,004 $ 448 $ — $ — $ 140 $ 3,723 Six Months Ended Nov 30, 2024 Termination Benefits Outside Consultants Validation Expenses Facilities Closeout Fees Regulatory Filings Other Total (in thousands) Balance at May 31, 2024 $ 568 $ 1,153 $ 373 $ — $ 6 $ 20 $ 2,120 Charges 563 3,675 1,177 2,563 22 691 8,691 Non-cash adjustments — — — (2,563) — — (2,563) Cash payments — (2,824) (1,102) — (28) (571) (4,525) Balance at November 30, 2024 $ 1,131 $ 2,004 $ 448 $ — $ — $ 140 $ 3,723

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Nov. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	ACCUMULATED OTHER COMPREHENSIVE LOSS Changes in each component of accumulated other comprehensive income, net of tax, are as follows: Three Months Ended Nov 30, 2024 (in thousands) Foreign currency translation income Balance at August 31, 2024 $ (3,267) Other comprehensive income, net of tax (481) Net other comprehensive income $ (481) Balance at November 30, 2024 $ (3,748) Six Months Ended Nov 30, 2024 (in thousands) Foreign currency translation income Balance at May 31, 2024 $ (4,365) Other comprehensive income, net of tax 617 Net other comprehensive income $ 617 Balance at November 30, 2024 $ (3,748)

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	6 Months Ended
	Nov. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements - Adopted There are no recently issued accounting pronouncements that have been adopted. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures This ASU improves the reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. June 1, 2024 The Company plans to adopt the new standard for fiscal year 2025 and does not expect there to be a material impact to the consolidated financial statements. ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures This ASU improves the income tax disclosure requirements on an annual basis by (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. June 1, 2025 The Company plans to adopt the new standard in the first quarter of fiscal year 2026 and does not expect there to be a material impact to the consolidated financial statements. ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-04): Disaggregation of Income Statement Expenses This ASU improves the disclosures about a public business entity's costs and expenses by requiring the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) included in each relevant income statement caption. June 1, 2027 The Company plans to adopt the new standard for the fiscal year 2028 and is assessing the impact to the consolidated financial statements. There have been no material changes to our critical accounting policies since our Annual Report on Form 10-K for fiscal year ended May 31, 2024.

Subsequent Events

Subsequent Events	6 Months Ended
	Nov. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTSOn December 24, 2024, the Company entered into an agreement to sell and leaseback the manufacturing facilities in Queensbury, NY and Glens Falls, NY for a purchase price of $5.5 million and $1.2 million, respectively and net proceeds of $4.8 million and $1.1 million, respectively. The Company also entered into a lease agreement with future lease payments of $4.6 million over seven years for Queensbury, NY and $0.4 million over three years for Glens Falls, NY.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Nov. 30, 2024	Aug. 31, 2024	Nov. 30, 2023	Aug. 31, 2023	Nov. 30, 2024	Nov. 30, 2023
Pay vs Performance Disclosure
Net income (loss)	$ (10,738)	$ (12,798)	$ (29,048)	$ 45,884	$ (23,536)	$ 16,836

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Nov. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Recently Issued Accounting Pr_2

Recently Issued Accounting Pronouncements (Policies)	6 Months Ended
	Nov. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Revenue Recognition	Revenue Recognition Under ASC 606, Revenue from Contracts with Customers Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposable revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations. Contract Balances with Customers A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements - Adopted There are no recently issued accounting pronouncements that have been adopted. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures This ASU improves the reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. June 1, 2024 The Company plans to adopt the new standard for fiscal year 2025 and does not expect there to be a material impact to the consolidated financial statements. ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures This ASU improves the income tax disclosure requirements on an annual basis by (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. June 1, 2025 The Company plans to adopt the new standard in the first quarter of fiscal year 2026 and does not expect there to be a material impact to the consolidated financial statements. ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-04): Disaggregation of Income Statement Expenses This ASU improves the disclosures about a public business entity's costs and expenses by requiring the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization and depletion) included in each relevant income statement caption. June 1, 2027 The Company plans to adopt the new standard for the fiscal year 2028 and is assessing the impact to the consolidated financial statements. There have been no material changes to our critical accounting policies since our Annual Report on Form 10-K for fiscal year ended May 31, 2024.

Divestitures (Tables)

Divestitures (Tables)	6 Months Ended
	Nov. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Summary of Major Classes of Assets Sold	The following table summarizes the major classes of assets sold on the date of the sale: (in thousands) As of February 15, 2024 Current assets: Inventories $ 4,203 Total current assets $ 4,203 Non-current assets: Property, plant and equipment, net $ 158 Intangible assets, net 20,781 Other assets 40 Total non-current assets $ 20,979 The following table summarizes the major classes of assets sold on the date of the sale: (in thousands) As of June 8, 2023 Current assets: Inventories $ 4,068 Prepaid expenses and other 2,000 Total current assets $ 6,068 Non-current assets: Property, plant and equipment, net $ 54 Intangible assets, net 17,629 Goodwill 25,980 Total non-current assets $ 43,663

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Nov. 30, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes net sales by Med Tech, Med Device and by geography: Three Months Ended November 30, 2024 Three Months Ended November 30, 2023 (in thousands) United States International Total United States International Total Net sales Med Tech $ 27,134 $ 4,420 $ 31,554 $ 20,947 $ 4,416 $ 25,363 Med Device 35,544 5,747 41,291 43,055 10,655 53,710 Total $ 62,678 $ 10,167 $ 72,845 $ 64,002 $ 15,071 $ 79,073 Six Months Ended November 30, 2024 Six Months Ended November 30, 2023 (in thousands) United States International Total United States International Total Net sales Med Tech $ 52,023 $ 7,500 $ 59,523 $ 43,189 $ 8,035 $ 51,224 Med Device 70,136 10,677 80,813 85,212 21,316 106,528 Total $ 122,159 $ 18,177 $ 140,336 $ 128,401 $ 29,351 $ 157,752
Contract Balances with Customers	The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Nov 30, 2024 May 31, 2024 Receivables $ 43,158 $ 43,610 Contract assets $ — $ — Contract liabilities $ 56 $ 391

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Nov. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Nov 30, 2024 May 31, 2024 Raw materials $ 28,445 $ 30,736 Work in process 6,596 6,772 Finished goods 30,877 23,108 Inventories $ 65,918 $ 60,616

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Nov. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Nov 30, 2024 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 177,540 $ (107,792) $ 69,748 Customer relationships 8,996 (5,823) 3,173 Trademarks 2,100 (2,052) 48 Licenses 3,837 (3,696) 141 $ 192,473 $ (119,363) $ 73,110 May 31, 2024 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 176,227 $ (102,468) $ 73,759 Customer relationships 9,028 (5,628) 3,400 Trademarks 2,100 (2,024) 76 Licenses 3,837 (3,689) 148 $ 191,192 $ (113,809) $ 77,383
Schedule of Future Amortization Expense	Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows: (in thousands) Remainder of 2025 $ 5,178 2026 10,175 2027 10,085 2028 10,036 2029 9,938 2030 and thereafter 27,698 $ 73,110

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Nov. 30, 2024
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following: (in thousands) Nov 30, 2024 May 31, 2024 Payroll and related expenses $ 13,139 $ 15,920 Outside services 8,982 8,962 Research and development 1,552 1,255 Royalties 2,088 2,575 Sales and franchise taxes 861 520 Deferred warranties 398 460 TSA Payable 6,459 6,259 Rebates 455 412 Accrued Freight 450 575 Accrued severance 1,524 1,486 Other 4,011 2,674 $ 39,919 $ 41,098

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Nov. 30, 2024
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding	The following table reconciles basic to diluted weighted-average shares outstanding: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Basic 40,922 40,219 40,787 40,030 Effect of dilutive securities — — — 73 Diluted 40,922 40,219 40,787 40,103 Securities excluded as their inclusion would be anti-dilutive 5,099 4,361 5,099 3,955

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Nov. 30, 2024
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	The table below summarizes net sales and gross margin by Med Tech and Med Device: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Med Tech net sales $ 31,554 $ 25,363 $ 59,523 $ 51,224 Gross profit 20,113 15,816 37,810 32,543 Gross margin 63.7 % 62.4 % 63.5 % 63.5 % Med Device net sales $ 41,291 $ 53,710 80,813 $ 106,528 Gross profit 19,793 24,446 38,820 $ 47,779 Gross margin 47.9 % 45.5 % 48.0 % 44.9 % Total net sales $ 72,845 $ 79,073 $ 140,336 $ 157,752 Gross profit 39,906 40,262 76,630 80,322 Gross margin 54.8 % 50.9 % 54.6 % 50.9 %
Summary of Net Sales by Geographic Area	The table below summarizes net sales by geographic area based on external customer location: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Net Sales United States $ 62,678 $ 64,002 $ 122,159 $ 128,401 International 10,167 15,071 18,177 29,351 Total $ 72,845 $ 79,073 $ 140,336 $ 157,752

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Nov. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: Fair Value at Nov 30, 2024 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 4,960 $ 4,960 Total Financial Liabilities $ — $ — $ 4,960 $ 4,960 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2024 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 4,728 $ 4,728 Total Financial Liabilities $ — $ — $ 4,728 $ 4,728
Fair Value Measurements Using Significant Unobservable Inputs	The table below presents the changes in fair value components of Level 3 instruments: Three Months Ended Nov 30, 2024 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, August 31, 2024 $ 4,804 Change in present value of contingent consideration (1) 156 Balance, November 30, 2024 $ 4,960 Six Months Ended November 30, 2024 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2024 $ 4,728 Change in present value of contingent consideration (1) 232 Balance, November 30, 2024 $ 4,960 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount.
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2024: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 4,960 Discounted cash flow Discount rate 10% Probability of payment 100% Projected fiscal year of payment 2025

Leases (Tables)

Leases (Tables)	6 Months Ended
	Nov. 30, 2024
Leases [Abstract]
Supplemental Balance Sheet Information	The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Nov 30, 2024 May 31, 2024 Assets Operating lease ROU asset Other assets $ 4,803 $ 5,804 Liabilities Current operating lease liabilities Other current liabilities 1,878 1,975 Non-current operating lease liabilities Other long-term liabilities 3,030 3,939 Total lease liabilities $ 4,908 $ 5,914 Nov 30, 2024 Weighted average remaining term (in years) 3.08 Weighted average discount rate 4.7 %
Lease Liability Schedule	The maturities of the lease liabilities for each of the following fiscal years is: (in thousands) Nov 30, 2024 Remainder of 2025 $ 1,077 2026 1,971 2027 983 2028 729 2029 and thereafter 515 Total lease payments $ 5,275 Less: imputed interest 367 Total lease obligations $ 4,908 Less: Current portion of lease obligations 1,878 Long-term lease obligations $ 3,030
Supplemental Cash Flow Information	The expenses on the Consolidated Statement of Operations were classified as follows: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Cost of sales $ 230 $ 219 $ 461 $ 416 Research and development 88 39 197 97 Sales and marketing 40 40 80 80 General and administrative 298 329 599 661 $ 656 $ 627 $ 1,337 $ 1,254 The following table presents supplemental cash flow and other information related to leases: Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,120 $ 1,064 ROU assets obtained in exchange for lease liabilities Operating leases $ — $ 381

Acquisition, Restructuring an_2

Acquisition, Restructuring and Other Items, Net (Tables)	6 Months Ended
	Nov. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Acquisition, restructuring and other items, net, consisted of: Three Months Ended Six Months Ended (in thousands) Nov 30, 2024 Nov 30, 2023 Nov 30, 2024 Nov 30, 2023 Legal (1) $ 56 $ 5,322 $ 410 $ 7,139 Mergers and acquisitions 737 252 737 252 Plant closure (2) 5,102 — 8,691 — Transition service agreement (3) (454) (177) (960) (323) Manufacturing relocation (4) — 689 — 1,277 Other (5) 427 102 1,301 1,055 Total $ 5,868 $ 6,188 $ 10,179 $ 9,400 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Plant closure expenses, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024. (3) Transition services agreements that were entered into with Merit and Spectrum. (4) Expenses to relocate certain manufacturing lines out of Queensbury, NY. (5) Included in the $1.1 million in other for the six months ended November 30, 2023 is $0.9 million of deferred financing fees that were written-off in conjunction with the sale of the Dialysis and BioSentry businesses and concurrent extinguishment of the debt. The following table provides a summary of our estimated costs associated with the original and modified Plan: Type of cost (in thousands) Total original estimated amount expected to be incurred Total modified estimated amount expected to be incurred Facilities closeout fees (1) $ 14,500 to $ 15,250 $ 16,000 to $ 17,000 Termination benefits 9,000 to 10,000 6,200 to 7,200 Outside consultants 9,000 to 10,000 7,500 to 8,500 Validation expenses 4,500 to 5,500 3,400 to 4,400 Regulatory filings 750 to 1,250 150 to 650 Other 750 to 1,250 150 to 650 $ 38,500 to $ 43,250 $ 33,400 to $ 38,400 (1) Included in the original and modified estimate is approximately $13.6 million and $13.3 million of non-cash charges for accelerated depreciation and building impairment, respectively. The table below presents the restructuring reserve for the three and six months ended November 30, 2024 : Three Months Ended Nov 30, 2024 Termination Benefits Outside Consultants Validation Expenses Facilities Closeout Fees Regulatory Filings Other Total (in thousands) Balance at August 31, 2024 $ 855 $ 994 $ 682 $ — $ — $ 74 $ 2,605 Charges 276 2,681 482 1,293 9 361 5,102 Non-cash adjustments — — — (1,293) — — (1,293) Cash payments — (1,671) (716) — (9) (295) (2,691) Balance at November 30, 2024 $ 1,131 $ 2,004 $ 448 $ — $ — $ 140 $ 3,723 Six Months Ended Nov 30, 2024 Termination Benefits Outside Consultants Validation Expenses Facilities Closeout Fees Regulatory Filings Other Total (in thousands) Balance at May 31, 2024 $ 568 $ 1,153 $ 373 $ — $ 6 $ 20 $ 2,120 Charges 563 3,675 1,177 2,563 22 691 8,691 Non-cash adjustments — — — (2,563) — — (2,563) Cash payments — (2,824) (1,102) — (28) (571) (4,525) Balance at November 30, 2024 $ 1,131 $ 2,004 $ 448 $ — $ — $ 140 $ 3,723

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Nov. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income, Net of Tax	Changes in each component of accumulated other comprehensive income, net of tax, are as follows: Three Months Ended Nov 30, 2024 (in thousands) Foreign currency translation income Balance at August 31, 2024 $ (3,267) Other comprehensive income, net of tax (481) Net other comprehensive income $ (481) Balance at November 30, 2024 $ (3,748) Six Months Ended Nov 30, 2024 (in thousands) Foreign currency translation income Balance at May 31, 2024 $ (4,365) Other comprehensive income, net of tax 617 Net other comprehensive income $ 617 Balance at November 30, 2024 $ (3,748)

Divestitures - Narrative (Detai

Divestitures - Narrative (Details) - Asset Purchase Agreement - USD ($) $ in Millions		3 Months Ended
	Jun. 08, 2023	Nov. 30, 2024
PICC And Midline Businesses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received		$ 34.5
Pre-tax book gain		6.7
Earn-out		$ 5.5
Earn-out period		2 years
Final transfer		$ 5
Dialysis and BioSentry
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received	$ 100
Pre-tax book gain	$ 47.8

Divestitures - Summary of Major

Divestitures - Summary of Major Classes of Assets Sold (Details) - Asset Purchase Agreement - USD ($) $ in Thousands	Feb. 15, 2024	Jun. 08, 2023
PICC And Midline Businesses
Business Combination, Separately Recognized Transactions [Line Items]
Inventories	$ 4,203
Current assets held for sale	4,203
Property, plant and equipment, net	158
Intangible assets, net	20,781
Other assets	40
Non-current assets held for sale	$ 20,979
Dialysis and BioSentry
Business Combination, Separately Recognized Transactions [Line Items]
Inventories		$ 4,068
Prepaid expenses and other		2,000
Current assets held for sale		6,068
Property, plant and equipment, net		54
Intangible assets, net		17,629
Goodwill		25,980
Non-current assets held for sale		$ 43,663

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 72,845	$ 79,073	$ 140,336	$ 157,752
United States
Disaggregation of Revenue [Line Items]
Net sales	62,678	64,002	122,159	128,401
International
Disaggregation of Revenue [Line Items]
Net sales	10,167	15,071	18,177	29,351
Med Tech
Disaggregation of Revenue [Line Items]
Net sales	31,554	25,363	59,523	51,224
Med Tech | United States
Disaggregation of Revenue [Line Items]
Net sales	27,134	20,947	52,023	43,189
Med Tech | International
Disaggregation of Revenue [Line Items]
Net sales	4,420	4,416	7,500	8,035
Med Device
Disaggregation of Revenue [Line Items]
Net sales	41,291	53,710	80,813	106,528
Med Device | United States
Disaggregation of Revenue [Line Items]
Net sales	35,544	43,055	70,136	85,212
Med Device | International
Disaggregation of Revenue [Line Items]
Net sales	$ 5,747	$ 10,655	$ 10,677	$ 21,316

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Narrative (Details) $ in Millions	6 Months Ended
	Nov. 30, 2024 USD ($)
Disaggregation of Revenue [Line Items]
Days after purchase after which pre-approval is required for product return	30 days
Restocking charge (as percent)	20%
Minimum remaining period prior to product expiration	12 months
Contract with customer, liability additions throughout current period	$ 0.2
Revenue recognized from contract liability balances in respective periods	$ 0.2
Minimum
Disaggregation of Revenue [Line Items]
Payment term	30 days
Maximum
Disaggregation of Revenue [Line Items]
Payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Contract Balances with Customers (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Revenue from Contract with Customer [Abstract]
Receivables	$ 43,158	$ 43,610
Contract assets	0	0
Contract liabilities	$ 56	$ 391

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Inventory Disclosure [Abstract]
Raw materials	$ 28,445	$ 30,736
Work in process	6,596	6,772
Finished goods	30,877	23,108
Inventories	$ 65,918	$ 60,616

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Nov. 30, 2024	May 31, 2024
Inventory Disclosure [Abstract]
Inventory valuation reserves	$ 3.3	$ 3.3

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 2,562	$ 3,562	$ 5,132	$ 7,187
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill	2 years		2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill	18 years		18 years

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	$ 192,473	$ 191,192
Accumulated amortization	(119,363)	(113,809)
Net carrying value, finite intangible items	73,110	77,383
Product technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	177,540	176,227
Accumulated amortization	(107,792)	(102,468)
Net carrying value, finite intangible items	69,748	73,759
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	8,996	9,028
Accumulated amortization	(5,823)	(5,628)
Net carrying value, finite intangible items	3,173	3,400
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	2,100	2,100
Accumulated amortization	(2,052)	(2,024)
Net carrying value, finite intangible items	48	76
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	3,837	3,837
Accumulated amortization	(3,696)	(3,689)
Net carrying value, finite intangible items	$ 141	$ 148

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2025	$ 5,178
2026	10,175
2027	10,085
2028	10,036
2029	9,938
2030 and thereafter	27,698
Net carrying value, finite intangible items	$ 73,110	$ 77,383

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Payables and Accruals [Abstract]
Payroll and related expenses	$ 13,139	$ 15,920
Royalties	2,088	2,575
Outside services	8,982	8,962
Research and development	1,552	1,255
Sales and franchise taxes	861	520
Rebates	455	412
Accrued Freight	450	575
Deferred warranties	398	460
TSA Payable	6,459	6,259
Accrued severance	1,524	1,486
Other	4,011	2,674
Total accrued liabilities	$ 39,919	$ 41,098

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Income Tax Disclosure [Abstract]
Estimated federal statutory income tax rate	1.70%	23.70%

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) shares in Thousands, $ in Millions				3 Months Ended		6 Months Ended
	Nov. 12, 2024	Nov. 14, 2023	Nov. 03, 2022	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023	Oct. 13, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges against income for share-based payment arrangements				$ 2.5	$ 1.9	$ 5.7	$ 6
Unrecognized compensation expenses related to share-based payment arrangements				$ 20		$ 20
Recognition period						3 years
2020 Stock And Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved increase of common stock reserve (shares)	3,200
Amount of shares issuable through two stock-based compensation plans (shares)				4,100		4,100
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Initial authorization (shares)								2,400
Approved increase of common stock reserve (shares)		1,500	1,950
Amount of shares issuable through two stock-based compensation plans (shares)				2,700		2,700

Equity (Details)

Equity (Details) - USD ($)	3 Months Ended
	Nov. 30, 2024	Aug. 31, 2024	Jul. 16, 2024
Share Repurchase Program [Line Items]
Share repurchases	$ 1,118,000	$ 552,000
Repurchase Program, July 2024
Share Repurchase Program [Line Items]
Share repurchases authorized (up to)			$ 15,000,000
Shares repurchased (in shares)	171,706	72,141
Share repurchases	$ 1,100,000	$ 500,000
Remaining available repurchases	$ 13,300,000

Earnings Per Share (Details)

Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Earnings Per Share [Abstract]
Basic (shares)	40,922	40,219	40,787	40,030
Effect of dilutive securities (shares)	0	0	0	73
Diluted (shares)	40,922	40,219	40,787	40,103
Securities excluded as their inclusion would be anti-dilutive (shares)	5,099	4,361	5,099	3,955

Segment and Geographic Inform_3

Segment and Geographic Information - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024 USD ($)	Nov. 30, 2023	Nov. 30, 2024 USD ($) segment	Nov. 30, 2023	May 31, 2024 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment			2
Assets | $	$ 291,550		$ 291,550		$ 317,671
International | International sales | Geographic Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage	14%	19.10%	13%	18.60%
United States | Long-lived assets | Geographic Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage			66%

Segment and Geographic Inform_4

Segment and Geographic Information - Summary of Net Sales by Product Category (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Segment Reporting Information [Line Items]
Net sales	$ 72,845	$ 79,073	$ 140,336	$ 157,752
Gross profit	$ 39,906	$ 40,262	$ 76,630	$ 80,322
Gross margin	54.80%	50.90%	54.60%	50.90%
Med Tech
Segment Reporting Information [Line Items]
Net sales	$ 31,554	$ 25,363	$ 59,523	$ 51,224
Gross profit	$ 20,113	$ 15,816	$ 37,810	$ 32,543
Gross margin	63.70%	62.40%	63.50%	63.50%
Med Device
Segment Reporting Information [Line Items]
Net sales	$ 41,291	$ 53,710	$ 80,813	$ 106,528
Gross profit	$ 19,793	$ 24,446	$ 38,820	$ 47,779
Gross margin	47.90%	45.50%	48%	44.90%

Segment and Geographic Inform_5

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 72,845	$ 79,073	$ 140,336	$ 157,752
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	62,678	64,002	122,159	128,401
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 10,167	$ 15,071	$ 18,177	$ 29,351

Fair Value - Fair Value of Asse

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Financial Liabilities
Contingent consideration for acquisition earn outs	$ 4,960	$ 4,728
Total Financial Liabilities	4,960	4,728
Level 1
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 2
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs	4,960	4,728
Total Financial Liabilities	$ 4,960	$ 4,728

Fair Value - Fair Value Measure

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Nov. 30, 2024	Nov. 30, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial liabilities, beginning balance	$ 4,804	$ 4,728
Change in present value of contingent consideration	156	232
Financial liabilities, ending balance	$ 4,960	$ 4,960

Fair Value - Summary Showing th

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) - Recurring $ in Thousands	Nov. 30, 2024 USD ($)	May 31, 2024 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration for acquisition earn outs	$ 4,960	$ 4,728
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration for acquisition earn outs	4,960	$ 4,728
Revenue based payments | Level 3 | Discounted cash flow
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration for acquisition earn outs	$ 4,960
Discount rate | Revenue based payments | Level 3 | Discounted cash flow
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unobservable Input	0.10
Probability of payment | Revenue based payments | Level 3 | Discounted cash flow | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unobservable Input	1

Fair Value - Additional Informa

Fair Value - Additional Information (Details) $ in Millions	Nov. 30, 2024 USD ($)
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$ 5

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Leases [Abstract]
Operating lease ROU asset	$ 4,803	$ 5,804
Current operating lease liabilities	1,878	1,975
Non-current operating lease liabilities	3,030	3,939
Total lease liabilities	$ 4,908	$ 5,914
Operating lease, right-of-use asset, statement of financial position, extensible list	Other assets	Other assets
Operating lease, liability, current, statement of financial position, extensible list	Other current liabilities	Other current liabilities
Operating lease, liability, noncurrent, statement of financial position, extensible list	Other long-term liabilities	Other long-term liabilities
Weighted average remaining term (in years)	3 years 29 days
Weighted average discount rate	4.70%

Leases - Liability Maturity Sch

Leases - Liability Maturity Schedule (Details) - USD ($) $ in Thousands	Nov. 30, 2024	May 31, 2024
Leases [Abstract]
Remainder of 2025	$ 1,077
2026	1,971
2027	983
2028	729
2028 and thereafter	515
Total lease payments	5,275
Less: imputed interest	367
Total lease liabilities	4,908	$ 5,914
Current operating lease liabilities	1,878	1,975
Non-current operating lease liabilities	$ 3,030	$ 3,939

Leases - Supplemental Statement

Leases - Supplemental Statement of Operations Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 656	$ 627	$ 1,337	$ 1,254
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense	230	219	461	416
Research and development
Lessee, Lease, Description [Line Items]
Non-cash lease expense	88	39	197	97
Sales and marketing
Lessee, Lease, Description [Line Items]
Non-cash lease expense	40	40	80	80
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 298	$ 329	$ 599	$ 661

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023
Leases [Abstract]
Operating cash flows from operating leases	$ 1,120	$ 1,064
ROU assets obtained in exchange for lease liabilities	$ 0	$ 381

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Apr. 05, 2024 USD ($)	Mar. 31, 2024 USD ($) payment	Mar. 10, 2015 patent	Jan. 11, 2012 patent	Nov. 30, 2024 USD ($) claim
The Delaware Action
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon | patent			3
C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon | patent				3
Becton, Dickinson and Company, C.R. Bard, Inc. and Bard Peripheral Vascular Inc.
Loss Contingencies [Line Items]
One-time lump sum payment		$ 7
Paid	$ 3
Number of annual payments | payment		6
Annual payments		$ 2.5
Potential additional annual payment percent		6%
Contingent payment		$ 3
Payable in current other liabilities					$ 7
Payable in other long-term liabilities					$ 8.8
Ports Product Claims
Loss Contingencies [Line Items]
Product liability claims | claim					50

Acquisition, Restructuring an_3

Acquisition, Restructuring and Other Items, Net - Schedule of Acquisition, Restructuring and Other Items, Net (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 5,868	$ 6,188	$ 10,179	$ 9,400
Legal
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	56	5,322	410	7,139
Mergers and acquisitions
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	737	252	737	252
Plant closure
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	5,102	0	8,691	0
Transition service agreement
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	(454)	(177)	(960)	(323)
Manufacturing relocation
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	0	689	0	1,277
Other
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 427	$ 102	$ 1,301	1,055
Deferred financing fees written-off				$ 900

Acquisition, Restructuring an_4

Acquisition, Restructuring and Other Items, Net - Summary of Estimated Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 5,868	$ 6,188	$ 10,179	$ 9,400
Plant closure
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	5,102	$ 0	8,691	$ 0
Total restructuring charges recorded to date	18,200		18,200
Original plan
Restructuring Cost and Reserve [Line Items]
Non-cash charges for accelerated depreciation and building impairment			13,600
Original plan | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	38,500		38,500
Original plan | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	43,250		43,250
Original plan | Facilities closeout fees | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	14,500		14,500
Original plan | Facilities closeout fees | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	15,250		15,250
Original plan | Termination benefits | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	9,000		9,000
Original plan | Termination benefits | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	10,000		10,000
Original plan | Outside consultants | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	9,000		9,000
Original plan | Outside consultants | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	10,000		10,000
Original plan | Validation expenses | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	4,500		4,500
Original plan | Validation expenses | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	5,500		5,500
Original plan | Regulatory filings | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	750		750
Original plan | Regulatory filings | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,250		1,250
Original plan | Other | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	750		750
Original plan | Other | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	1,250		1,250
Modified plan
Restructuring Cost and Reserve [Line Items]
Non-cash charges for accelerated depreciation and building impairment			13,300
Modified plan | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	33,400		33,400
Modified plan | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	38,400		38,400
Modified plan | Facilities closeout fees | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	16,000		16,000
Modified plan | Facilities closeout fees | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	17,000		17,000
Modified plan | Termination benefits | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	6,200		6,200
Modified plan | Termination benefits | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	7,200		7,200
Modified plan | Outside consultants | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	7,500		7,500
Modified plan | Outside consultants | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	8,500		8,500
Modified plan | Validation expenses | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	3,400		3,400
Modified plan | Validation expenses | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	4,400		4,400
Modified plan | Regulatory filings | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	150		150
Modified plan | Regulatory filings | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	650		650
Modified plan | Other | Minimum
Restructuring Cost and Reserve [Line Items]
Estimated costs	150		150
Modified plan | Other | Maximum
Restructuring Cost and Reserve [Line Items]
Estimated costs	$ 650		$ 650

Acquisition, Restructuring an_5

Acquisition, Restructuring and Other Items, Net - Restructuring Reserve (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Nov. 30, 2024	Nov. 30, 2024
Restructuring Reserve [Roll Forward]
Beginning balance	$ 2,605	$ 2,120
Charges	5,102	8,691
Non-cash adjustments	(1,293)	(2,563)
Cash payments	(2,691)	(4,525)
Ending balance	3,723	3,723
Termination benefits
Restructuring Reserve [Roll Forward]
Beginning balance	855	568
Charges	276	563
Non-cash adjustments	0	0
Cash payments	0	0
Ending balance	1,131	1,131
Outside consultants
Restructuring Reserve [Roll Forward]
Beginning balance	994	1,153
Charges	2,681	3,675
Non-cash adjustments	0	0
Cash payments	(1,671)	(2,824)
Ending balance	2,004	2,004
Validation expenses
Restructuring Reserve [Roll Forward]
Beginning balance	682	373
Charges	482	1,177
Non-cash adjustments	0	0
Cash payments	(716)	(1,102)
Ending balance	448	448
Facilities closeout fees
Restructuring Reserve [Roll Forward]
Beginning balance	0	0
Charges	1,293	2,563
Non-cash adjustments	(1,293)	(2,563)
Cash payments	0	0
Ending balance	0	0
Regulatory filings
Restructuring Reserve [Roll Forward]
Beginning balance	0	6
Charges	9	22
Non-cash adjustments	0	0
Cash payments	(9)	(28)
Ending balance	0	0
Other
Restructuring Reserve [Roll Forward]
Beginning balance	74	20
Charges	361	691
Non-cash adjustments	0	0
Cash payments	(295)	(571)
Ending balance	$ 140	$ 140

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2024	Nov. 30, 2023	Nov. 30, 2024	Nov. 30, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 196,582	$ 427,804	$ 205,586	$ 378,296
Other comprehensive income (loss), net of tax	(481)	945	617	15
Ending Balance	186,768	$ 401,226	186,768	$ 401,226
Foreign currency translation income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(3,267)		(4,365)
Other comprehensive income, net of tax	(481)
Other comprehensive income (loss), net of tax	(481)		617
Ending Balance	$ (3,748)		$ (3,748)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Dec. 24, 2024	Nov. 30, 2024
Subsequent Event [Line Items]
Total lease payments		$ 5,275
Subsequent Event | Manufacturing facilities in Queensbury, NY
Subsequent Event [Line Items]
Purchase price	$ 5,500
Net proceeds	4,800
Total lease payments	$ 4,600
Financial obligation period	7 years
Subsequent Event | Manufacturing facilities in Glens Falls, NY
Subsequent Event [Line Items]
Purchase price	$ 1,200
Net proceeds	1,100
Total lease payments	$ 400
Financial obligation period	3 years